Abstract

PurposeThe most common virus vector used in gene therapy research for ophthalmologic diseases is the adeno-associated virus (AAV) vector, which has been used successfully in a number of preclinical and clinical studies. It is important to evaluate novel AAV vectors in animal models for application of clinical gene therapy. The AAV-DJ (type 2/type 8/type 9 chimera) was engineered from shuffling eight different wild-type native viruses. In this study, we investigated the efficiency of gene transfer by AAV-DJ injections into the retina.MethodsOne microliter of AAV-2-CAGGS-EGFP or AAV-DJ-CAGGS-EGFP vector at a titer of 1.4 × 10e12 vg/ml was injected intravitreally or subretinally in each eye of C57BL/6 mice. We evaluated the transduction characteristics of AAV-2 and -DJ vectors using fluorescence microscopy and electroretinography.ResultsThe results confirmed that AAV-DJ could deeply transfer gene to photoreceptor layer with intravitreal injection and has an efficient gene transfer to various cell types especially the Mueller cells in the retina. Retinal function was not affected by AAV-DJ infection or ectopic EGFP expression.ConclusionsThe AAV-DJ vector efficiently induces the reporter gene in both the inner and outer murine retina without functional toxicity. These data indicated that the AAV-DJ vector is a useful tool for the gene therapy research targeting retinal disorders.

Highlights

  • No fundamental therapies exist for retinal degenerative diseases such as retinitis pigmentosa and dry age-related macular degeneration, numerous surgical and medical innovations have been introduced to treat cataract and glaucoma, which were the leading causes of blindness worldwide

  • The most common virus vector used in gene therapy research for ophthalmologic diseases is the adeno-associated virus (AAV) vector, which has been used in a number of successful preclinical and clinical studies

  • AAV-DJ showed a rapid rise in fluorescence intensity, and its fluorescence intensity (n = 6 retinas) was significantly higher at 1 week after injection than that of AAV-2 (n = 6 retinas; p < 0.001, unpaired t -test) (Fig. 1B)

Read more

Summary

Introduction

No fundamental therapies exist for retinal degenerative diseases such as retinitis pigmentosa and dry age-related macular degeneration, numerous surgical and medical innovations have been introduced to treat cataract and glaucoma, which were the leading causes of blindness worldwide. Gene therapy is a promising candidate to prevent blindness in these patients. The most common virus vector used in gene therapy research for ophthalmologic diseases is the adeno-associated virus (AAV) vector, which has been used in a number of successful preclinical and clinical studies Evaluation of AAV-DJ vector for retinal gene therapy.

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call